Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
First-time investors can benefit greatly from expert advice. Learn key strategies to navigate the investment landscape effectively.
28,248 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Micron Technology is at a pivotal moment as AI-related demand collides with a cyclical memory market. Shares have sur...
Qualcomm surged in early trading after landing Meta Platforms as a data center customer for its Dragonfly chip, then ...
SpaceX debt is signaling risk far larger than its rating label suggests, as bond markets price in a heavier risk prem...
SpaceX is lining up a blockbuster IPO that could outpace the entire 2025 IPO slate. Analysts estimate a multi-billion...
A new ETF focused on CTAs began trading this week, giving U.S. investors direct exposure to trend-following across mu...
The White House has tapped a real-estate heir as acting director of national intelligence, a move that drew sharp que...
A top chip maker delivered a surprising quarterly beat, reviving investor appetite and igniting a debate over AI memo...
U.S. oil refiners are set for a historic profit surge as supply disruptions and stronger demand push refining margins...
A rising crypto platform seeks to give retail investors access to IPO pricing by delivering on-chain, tokenized share...
Intel has surged 116% in the past month as AI demand strengthens data-center demand and early talks of a potential Ap...
Major brokerages issued new research on top names like Airbnb, Broadcom, Chipotle, and NVIDIA as investors rotate str...